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ABSTRACT
Microglia act as sensors of injury in the brain, favoring its homeostasis. Their activation and polarization toward a proinflammatory
phenotype are associated with injury and disease. These processes are linked to a metabolic reprogramming of the cells, characterized
by high rates of glycolysis and suppressed oxidative phosphorylation. This metabolic switch can be reproduced in vitro by microglial
stimulation with LPS plus IFN-g. To understand the mechanisms regulating mitochondrial respiration abolishment, we examined
potential alterations in mitochondrial features during this switch using rat primary microglia. Cells did not show any change in
mitochondrial membrane potential, suggesting a limited impact in the mitochondrial viability. We provide evidence that reverse
operation of F0F1-ATP synthase contributes to mitochondrial membrane potential. In addition, we studied the possible implication of
mitochondrial dynamics in the metabolic switch using the mitochondrial division inhibitor-1 (Mdivi-1), which blocks dynamin-related
protein 1 (Drp1)–dependent mitochondrial fission. Mdivi-1 significantly reduced the expression of proinflammatory markers in LPS plus
IFN-g–treated microglia. However, this inhibition did not lead to a recovery of the oxidative phosphorylation ablation by LPS plus IFN-
g or to a microglia repolarization. Altogether, these results suggest that Drp1-dependent mitochondrial fission, although potentially
involved in microglial activation, does not play an essential role in metabolic reprogramming and repolarization of microglia.
ImmunoHorizons, 2021, 5: 615–626.
INTRODUCTION
Microglial cells are the resident immune cells of the CNS. They
contribute to the tissue development, integrity and homeostasis
through an active surveillance process (1, 2) that can lead to
different states of activation. Microglia display an enormous
plasticity of responses to injury, ranging from effects that may
contribute to neuroinflammation and, eventually, tissue damage,
to essential responses for regenerative processes (3). These
mechanisms are associated with a broad spectrum of activation
states, which are in turn related to molecular changes and
adaptations (4). One of these adaptive mechanisms is the meta-
bolic reprogramming of microglia and other immune cells in
response to immune activation (58). Similar to macrophages
(6, 7), microglia exposed to proinflammatory stimulus shift
their metabolism from oxidative phosphorylation (OXPHOS) to
aerobic glycolysis (9, 10), in an event similar to the Warburg
effect suffered by cancer cells (7). This metabolic reprogramming
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is essential to activate cellular defense mechanisms and to man-
age various microenvironments in inflamed tissue (7, 1113).
Moreover, these cells overexpress inflammatory markers, such
as IL-1b, TNF-a, or inducible NO synthase (iNOS), which takes
part in the metabolism of arginine. In contrast, macrophages
exposed to anti-inflammatory stimuli are primarily characterized
by OXPHOS and increased fatty acid oxidation for ATP synthe-
sis (6, 12), a fact that has not been corroborated in microglia
cells. This anti-inflammatory activation is commonly accompa-
nied by an increase in the expression of specific markers, such
as arginase 1 (Arg1), which competes with iNOS to hydrolyze
arginine to ornithine (14), or the mannose receptor (MNR).
As mitochondria are crucial organelles in OXPHOS-related
metabolism of the cells, we hypothesized that disbalances in
their integrity or dynamics may contribute to microglia meta-
bolic reprogramming toward a glycolytic phenotype. Mitochon-
drial dynamics, involving processes of both fusion and fission,
are known to contribute to cell homeostasis and the mainte-
nance of other mitochondrial functions (15). Basal mitochon-
drial fission is required for mitochondrial trafficking to
synapses, mitochondrial quality control, and brain development
(16). Misbalances in these dynamic mechanisms are thought to
contribute to the development of various neurologic disorders
(1719). Moreover, these processes are associated with the pro-
duction of reactive oxygen species (ROS). Mitochondrial fission
is triggered by the dynamin-related protein 1 (Drp1) recruit-
ment from the cytosol to the outer mitochondrial membrane,
which is mediated by different adaptor proteins (20, 21). Lately,
the pharmacological inhibition of Drp1 with the mitochondrial
division inhibitor 1 (Mdivi-1), a quinazolinone derivative, has
become a promising strategy to analyze the physiological and
pathological role of mitochondrial fission (22).
We tested whether mitochondria are functionally affected
during metabolic reprogramming conditions. Moreover, we
assessed whether mitochondrial fission is involved in microglia
metabolic reprogramming. We used Mdivi-1 to block Drp1-
dependent mitochondrial fission in vitro and found that,
whereas this inhibition leads to a modulation of the expression
of inflammatory markers in microglial cells, this is not sufficient
to alter the metabolic switch suffered by the cells, in sharp con-
trast with the results reported in a previous study (9). Further-
more, as Mdivi-1 treatment generated a decrease in iNOS
expression, we have assessed whether this outcome was suffi-
cient to favor a repolarization process in microglia.
MATERIALS AND METHODS
Animals
All experiments were performed according to the procedures
approved by the Ethics Committee of the University of the Bas-
que Country. Animals were handled in accordance with the
European Communities Council Directive and were kept under
conventional housing conditions (22 6 2C, 55 6 10% humid-
ity, and 12-h day/night cycle) at the animal facilities. The study
was carried out in compliance with the Animal Research:
Reporting of In Vivo Experiments guidelines. All possible
efforts were made to minimize animal suffering and the num-
ber of animals used.
Microglial culture
Primary mixed glial cultures were prepared from the cerebral
cortex of neonatal rats (P0-P2). After 1015 d in culture, micro-
glia were isolated by mechanical shaking (400 rpm, 1 h) and
purified by plating them on noncoated bacterial grade Petri
dishes (Sterilin; Thermo Fisher Scientific), as previously
described (23). Microglial cells obtained with this procedure
were cultured in DMEM (Life Technologies) supplemented
with 10% FBS (Life Technologies). Cultures of microglia were
practically pure of microglial cells (>99%) (24).
Microglial cells were polarized with specific stimuli. To
generate an anti-inflammatory phenotype in these cells, they
were treated for 24 h with IL-4 (20 ng/ml; PeproTech) and IL-
13 (50 ng/ml; PeproTech). In contrast, proinflammatory micro-
glia were generated with a treatment of both LPS (10 ng/ml;
Sigma-Aldrich) and IFN-g (20 ng/ml; PeproTech) for 24 h. In
the experiments for the study of the proinflammatory activation
time course, the LPS plus IFN-g treatment was maintained for
2, 6, or 24 h prior to the metabolic analysis. The repolarization
protocol implied a 24-h proinflammatory activation followed by
a treatment with the anti-inflammatory stimuli for the same
amount of time. Mdivi-1 (50 mM, 24 h) was applied alone or in
combination with pro- and anti-inflammatory factors.
Immunofluorescence analysis
Several immunocytochemistry assays were performed on the
cells in different conditions. Cells in culture were fixed in 4%
p-formaldehyde in PBS and processed for immunocytochemis-
try, as previously described (25). Primary Abs were used were
follows: Iba1 (1:500; Wako Chemicals), iNOS (1:500; BD Bio-
sciences), a proinflammatory marker, and MNR C type 1
(MRC1; 1:1000; Abcam), specific for anti-inflammatory cells. As
secondary Abs, we used goat anti-rabbit Alexa Fluor 488 (1:250;
Invitrogen) and goat anti-mouse Alexa Fluor 594 (1:250; Invi-
trogen). The morphology of microglial cells was analyzed using
the Iba1 immunofluorescence, as the whole soma was stained
by it. The circularity of the cell was calculated as defined in the
ImageJ software; a circular shape would approach a value of 1.
All the image analysis was performed with the ImageJ software
(National Institutes of Health). Immunoreactivity of the differ-
ent markers was calculated as the fluorescence intensity nor-
malized to the number of cells in the selected field of view.
Cell viability assays
Microglial viability was assessed using both the calcein AM dye
(Invitrogen) and the CytoTox 96 Non-Radioactive Cytotoxicity
Assay (Promega).
For the performance of the calcein assay, cells were incu-
bated with 0.5 mM of the dye for 30 min at 37C. The wells
















were then washed with PBS, and the number of viable cells were
calculated with a Synergy HT fluorimeter/spectrophotome-
ter reader (BIO-TEK INSTRUMENTS) with 485-nm excita-
tion and at 528 nm of emission wavelengths. A well with
PBS was also measured in each experiment to subtract its
values as a background control. The results are expressed
as the relative percentage of cellular death with respect to
nontreated microglial cells.
For the CytoTox 96 Non-Radioactive Cytotoxicity Assay,
culture supernatants were harvested from the plate, mixed
with the specific assay buffer and incubated for 30 min at 37C.
The reaction was then stopped, and the absorbance at 490 nm
was immediately recorded in the fluorimeter. The levels of
absorbance are associated with the amount of lactate dehydro-
genase in the medium, a stable cytosolic enzyme that is
released upon cellular death and its consequent lysis. All the
data obtained through both assays was analyzed using Gen5
software (BIO-TEK INSTRUMENTS).
ROS analysis
The production of ROS by control microglia and microglia
treated with LPS and IFN-g was measured using the CM-
H2DCFDA dye (Invitrogen). Specifically, cells were incubated
with the dye for 30 min. The wells were then washed with
PBS, and the number of viable cells were calculated with a Syn-
ergy HT fluorimeter/spectrophotometer reader (BIO-TEK
INSTRUMENTS) with 485-nm excitation and at 528 nm of
emission wavelengths, following the guidelines of the
manufacturer.
Quantitative RT-PCR
Total RNA of microglial cells was extracted using TRIzol
(Invitrogen) according to the manufacturers instructions.
Afterwards, 1 mg of this RNA was used to perform a retrotran-
scription protocol, using SuperScript III Reverse Transcrip-
tase (200 U/ml; Invitrogen) and random hexamers as primers
(Promega).
Real-time quantitative PCRs (qPCRs) were conducted in a
Bio-Rad Laboratories CFX96 real-time PCR detection system,
as previously described (26). The reactions were performed
using SYBR Green as a DNA-binding dye and specific primers
for anti-inflammatory and proinflammatory markers (Table I).
These primers were designed using Primer Express Software
(Applied Biosystems) at exon junctions to avoid genomic DNA
amplification. The cycling conditions comprised 3 min of poly-
merase activation at 95C and 40 cycles consisting of 10 s at
95C and 30 s at 60C. After every qPCR reaction, the melting
curve was assessed to check the specificity of the amplification.
The amount of cDNA was quantified using a standard curve
from a pool of cDNA obtained from the different conditions of
each experiment. Subsequently, the results were normalized
using a normalization factor based on the geometric mean of
housekeeping genes (Table I) obtained for each condition using
the geNorm v3.5 software (27).
Mitochondrial membrane potential and mitochondrial
calcium measurements
For quantification of mitochondrial membrane potential
(DCm), we use rhodamine 123 dye (Rh123) under quenching
concentrations, a reliable dye for confocal microscopy analysis
of DCm (2830). Microglial cells were loaded with Rh123 (10
mM) for 15 min in medium without phenol red. After this,
microglia were washed for 10 min in the same medium. Living
cell imaging was performed with a 63 objective in an inverted
Leica TCS SP2-AOBS confocal microscope at an acquisition
rate of one frame every 15 s for 5 min. In this short-term proto-
col, no cell toxicity was detected with Rh123. After obtaining
some basal images, carbonyl cyanide 4-(trifluoromethoxy) phe-
nylhydrazone (FCCP) (1 mM), an uncoupler of the mitochon-
drial OXPHOS, was added to the plates, and the increase in the
Rh123 fluorescence level was measured to determine the mem-
brane potential. For each plate, a homogenous population of
20 cells was selected in the field of view, and the background
fluorescence signal was subtracted from the individual values.
For the measurement of the mitochondrial calcium content,
time-lapse images were acquired using a 63 objective in a
Leica TCS STED CW SP8 confocal microscope, at an acquisi-
tion rate of one frame every 15 s for 5 min. Cells were loaded
with 1 mM Fluo-4 (Thermo Fisher Scientific) in HBSS (Ca21-
and Mg21-free) with 0.5 mM EGTA for 30 min at 37C. Subse-
quently, microglial cells were washed, and after obtaining some
basal images, 1 mM FCCP was added to depolarize the mito-
chondrial membrane and force the release of Ca21 from mito-
chondrial matrix to the cytosol. The analysis was made as
described above.
Mitochondrial morphology analysis
For the quantification of mitochondrial length, living cell imag-
ing was performed on microglial cells loaded with Rh123 (50
nM) for 20 min. Mitochondrial images were taken using a Zeiss
LSM 800 confocal microscope at 40 magnification and a pixel
resolution of 1024  1024 and analyzed using the Object Ana-
lyzer tool of Huygens image analysis software (version 20.10;
Scientific Volume Imaging, B.V.). First, background noise was
removed using the maximum fluorescence intensity value of
Rh123 in the nuclear region. Afterwards, a size filter was
applied to remove objects smaller than mitochondria (38
voxels 5 0.06 mm3) (31). Next, a watershed segmentation
was performed using a s value of 0.2 to separate objects
that were not discriminated in the raw images because of
the inherent resolution limit of confocal microscopy. After
this preprocessing, the average length of each mitochon-
drial object per cell was calculated.
OXPHOS and glycolysis analysis
Real-time measurements of oxygen consumption rate (OCR),
extracellular acidification rate (ECAR), and glycolytic proton
efflux rate (glycoPER) were performed using a Seahorse XFe96
Extracellular Flux Analyzer (Agilent Technologies), following
















manufacturers instructions to carry out the XF Cell Mito Stress
Test Kit or the XF Glycolytic Rate Assay Kit (Agilent Technolo-
gies). Microglia cells were seeded as a monolayer in the XF96
microplate. Before the assay, cells were washed and equilibrated
in the XF Assay modified DMEM For 30 min at 37C.
For the performance of the XF Cell Mito Stress Test Kit,
the real levels of OCR were determined in response to the
sequential addition of oligomycin (2 mM), FCCP (1 mM), and
rotenone/antimycin A (0.5 mM). Specifically, basal mitochondrial
respiration was calculated subtracting the OCR rate after rote-
none/antimycin A addition from basal OCR. The spare respira-
tory capacity was obtained by subtracting the basal respiration
level from the maximum rate measurement after addition of
FCCP; ATP-linked OCR was determined by subtracting oligomy-
cin-induced OCR from basal OCR. For the acute treatment with
LPS plus IFN-g, these factors were added to the cells after the
basal measurement of OCR and prior to the addition of
oligomycin.
For the measurement of the basal glycoPER, the XF Glyco-
lytic Rate Assay Kit was carried out. This test includes the
sequential addition of rotenone/antimycin A (0.5 mM), and 2-
deoxyglucose (50 mM). The glycoPER corresponds to the pro-
ton efflux rate derived from glycolysis (discounting the effect of
CO2-dependent acidification included in the ECAR measure-
ment) All these parameters were obtained using the specific
Agilent Report Generator. For each single experiment, eight
replicates were performed.
Data analysis
All the data shown in the figures are presented as the mean 6
SEM. All the statistical analyses were performed with Graph-
Pad Prism 8.0 (GraphPad Software). Specifically, every compar-
ison between two groups was analyzed using a paired Student
two-tailed t test. Comparisons among multiple groups were
analyzed by one-way ANOVA followed by Bonferroni multiple
comparison tests for post hoc analysis. Statistical significance
was considered at p < 0.05.
RESULTS
Metabolic reprogramming in microglia is not associated
with mitochondrial damage
To test whether microglia metabolic reprogramming from
OXPHOS to glycolysis upon proinflammatory stimulation is
associated with mitochondrial damage, we set up an in vitro
protocol to study the metabolic switch, and we measured OCR
and ECAR in real time as indicative of mitochondrial respira-
tion and glycolysis, respectively. Cells treated with classical
proinflammatory stimuli (LPS and IFN-g) showed a flat profile
regarding OXPHOS, and all the parameters (basal OCR, ATP-
linked respiration, and spare respiratory capacity) related to
this molecular process were practically abolished (Fig. 1A), as
previously described (32). This suggests a metabolism shift
from OXPHOS to glycolysis to rapidly obtain energy.
Conversely, microglia treated with anti-inflammatory factors
(IL-4 and IL-13) showed a significant increase in basal OCR,
spare respiratory capacity, and ATP-linked respiration, thus
indicating that mitochondrial OXPHOS was boosted (Fig. 1A).
In contrast, ECAR measurement showed an increase in basal
glycolysis in both proinflammatory and anti-inflammatory
microglia (Fig. 1B), suggesting that activated microglia have
higher energetic demands. Moreover, inhibition of mitochon-
drial F0F1-ATP synthase with oligomycin, thus blocking
OXPHOS, increased the glycolytic rate in control and anti-
inflammatory microglia but not in proinflammatory microglia
(Fig. 1B). Finally, the basal ratio between mitochondrial OCR
and the glycoPER was significantly diminished in proinflamma-
tory microglia (Fig. 1C). These results further support the idea
that proinflammatory microglia metabolism relies exclusively
on glycolysis.
In other immune cells, such as dendritic cells, the metabolic
switch to glycolysis occurs within minutes after TLR activation
with LPS (33). However, microglia acute treatment with LPS
did not induce any change in OCR-associated parameters (Fig.
1D). Time course analysis demonstrated that the metabolic
switch began to occur at 2 h, was clear at 6 h, and completed
at 24 h (Fig. 1E).
Because OXPHOS takes place in the mitochondrial inner
membrane and is determinant for H1 movement and DCm
maintenance, the arrest of mitochondrial OXPHOS by proin-
flammatory stimuli could induce a collapse in DCm. To check
whether DCm was altered in microglia treated with proinflam-
matory stimuli, we performed live cell imaging of Rh123 fluo-
rescent dye in microglia under quenching conditions (28).
Addition of the mitochondrial OXPHOS uncoupler FCCP pro-
voked the release of Rh123 from the mitochondria and conse-
quently increased its cytoplasmic fluorescence 2-fold over
baseline (100%) in control microglia as well as in microglia
treated with LPS plus IFN-g (Fig. 2A), indicating that basal
mitochondrial potential is maintained in proinflammatory
microglia, despite the arrest of OXPHOS. To further assess
mitochondrial integrity, we measured resting [Ca21]mit by
recording [Ca21]cyt upon addition of FCCP in the absence of
extracellular Ca21, which is indicative for [Ca21]mit (34). Again,
we observed no significant differences in the release of mito-
chondrial calcium to the cytosol after the addition of FCCP
(Fig. 2B). Moreover, proinflammatory stimulation of microglia
induced a significant increase in ROS production, as revealed
with the dichlorofluorescein diacetate (DCFDA; Invitrogen)
dye (Fig. 2C), despite the blockage of OXPHOS. All these
results suggest that proinflammatory activation and its subse-
quent lack of OXPHOS activity in microglia are not related to
and it does induce any mitochondrial dysfunction or alteration
in DCm.
Maintaining DCm is essential to prevent the release of
proapoptotic factors into the cytosol and subsequent cell death.
Indeed, despite the blockage of OXPHOS, LPS plus IFN-g stim-
ulation did not induce any significant microglia cell death (Fig.
2D). We hypothesized that DCm could be maintained in cells
















with respiration inhibited by the reverse operation of F0F1-ATP
synthase and the adenine nucleotide translocase (ANT), which
pump H1 out of the matrix (35). To test this hypothesis, we
analyzed the impact of the F0F1-ATP synthase and ANT in cell
viability and DCm. Indeed, treatment of LPS plus IFN-
gstimulated microglia with oligomycin, an F0F1-ATP synthase
inhibitor, and induced a significant increase in microglia cell
death (Fig. 2D). In contrast, bongkrekic acid, an inhibitor of
ANT (36), did not induce microglia cell death (Fig. 2D).
Accordingly, a role of F0F1-ATP synthase in mitochondrial
DCm maintenance in proinflammatory microglia was further
corroborated by live cell imaging of tetramethylrhodamine
ethyl ester, a fluorescent dye that accumulates in active
mitochondria. Addition of oligomycin induced a significant
decrease in DCm in proinflammatory microglia but not in con-
trol microglia (Fig. 2E), supporting the idea that the formers
mitochondrial integrity depends on the activity of the ATP
synthase.
Mitochondrial fission inhibition does not reverse
mitochondrial metabolic reprogramming
Previous data have showed that activation of microglia with
LPS induced a transient shortening of mitochondria by fission
at 2 h. Similarly, we detected a shortening of mitochondrial
length at 2 h after LPS plus IFN-g treatment, an effect that was
reverted in the presence of the mitochondrial fission inhibitor
FIGURE 1. Robust metabolic reprogramming to glycolytic pathway after 24 h of proinflammatory stimulation in microglia.
(A) Representative experiment of OCR measurements in control microglia and in microglia after 24 h of proinflammatory (LPS plus IFN-g) and anti-
inflammatory (IL-4 plus IL-13) stimulations. Histograms show metabolic parameters obtained by the analysis of this metabolic profile compared
with control cells (n 5 7 independent experiments). (B) ECAR measurement obtained by the secretion of lactate of control microglia and microglia
after 24-h incubation with pro- and anti-inflammatory factors (n 5 7). Histograms show the basal level of this parameter as well as the increase in
provocation by the acute treatment with oligomycin relative to the control cells. Statistical analysis was performed by one-way ANOVA followed by
Bonferroni post hoc test. (C) Ratio between the basal OCR and the basal glycoPER control and both proinflammatory and anti-inflammatory
microglia after 24 h of stimulation. These parameters were obtained using the XF Glycolytic Rate Assay test (n 5 3 independent experiments). (D)
Metabolic profile of microglia after acute treatment with LPS and IFN-g. This treatment was added after the basal measurement of OCR and prior
to the addition of oligomycin (n 5 3). (E) Metabolic profile of microglia treated during different time lapses with LPS and IFN-g. Histograms show
the metabolic parameters compared with control cells (n 5 3). Data are presented as means 6 SEM. Unless otherwise stated, a Student t test was
used to analyze the data. *p < 0.05, **p < 0.005, ***p < 0.001.
















FIGURE 2. Proinflammatory microglia maintain mitochondrial integrity upon F0F1-ATP synthase activity blockade.
(A) Measurement of mitochondrial potential represented as the increase in cytoplasmic Rh123 fluorescence measured after acute exposure to
FCCP in control and LPS plus IFN-g–treated microglia (n 5 50–75 cells from three independent experiments). Scale bar, 20 mM. (B) Measurement
of mitochondrial-specific calcium represented as the increase in cytoplasmic Fluo-4 fluorescence in a Ca21-free medium after exposure to FCCP
in control and LPS plus IFN-g–treated cells (n 5 50–75 cells from three independent experiments). (C) ROS quantification in control and proinflam-
matory cells (n 5 3 experiments performed in triplicate). (D) Microglial viability after 24-h treatment with LPS plus IFN-g, oligomycin, and/or bongk-
rekic acid compared with control cells. One-way ANOVA followed by Bonferroni post hoc analysis was used (n 5 3 experiments performed in
triplicate). (E) Effect of F0F1-ATP synthase inhibitor oligomycin in mitochondrial potential of control and LPS plus IFN-g–treated cells (n 5 70–80
cells from three independent experiments). Data are presented as means 6 SEM. Unless otherwise stated, a Student t test was used to analyze the
data. **p < 0.005, ***p < 0.001.
















Mdivi-1 (9, 37) (Supplemental Fig. 1). Because microglia meta-
bolic switch has been associated previously with mitochondrial
fission (9), we further analyzed this hypothesis in our cultures
using Mdivi-1. First, we assessed whether the Mdivi-1
treatment would have an effect on microglia itself. A 24-h
treatment with Mdivi-1 (50 mM) provoked a morphological
change in microglia, with a significant increase in cytoplasm
circularity, indicating that Mdivi-1 treatment induces an
FIGURE 3. Mitochondrial fission inhibition reduces the microglial inflammatory markers.
(A) Representative images of Iba11 control and Mdivi-1–treated microglia. Right column shows Iba11 and DAPI staining (merge). Scale bar, 25 mm.
Histogram represents the circularity of the cells as calculated by ImageJ software (n 5 200 cells from three independent experiments). (B) Expres-
sion of anti-inflammatory (MNR) and proinflammatory mediators (iNOS) in control and Mdivi-1–treated microglia (n 5 4 independent experiments
performed with duplicates). (C) Microglial viability in control and Mdivi-1 cells, measured by both calcein assay and the quantification of lactate
dehydrogenase release to the medium, indicative of cell death (n 5 3 experiments performed in triplicate). (D) Representative immunostaining of
MNR and iNOS in control microglia as well as in cells treated with LPS plus IFN-g or Mdivi-1 and LPS plus IFN-g. Scale bar, 40 mm. Histograms rep-
resent the mean fluorescence of the staining per cell (n 5 four independent experiments performed with duplicates). One-way ANOVA followed
by Bonferroni post hoc analysis was used. (E) Quantitative real-time PCR of proinflammatory (left) and an anti-inflammatory mediator (right) in con-
trol microglia as well as in microglia treated with Mdivi-1, LPS plus IFN-g, and Mdivi-1 plus LPS plus IFN-g (n 5 4 experiments performed in dupli-
cate). Data are expressed relative to the expression in LPS plus IFN-g. One-way ANOVA followed by Bonferroni post hoc analysis was used. Data
are presented as means 6 SEM. Unless otherwise stated, a Student t test was used to analyze the data. *p < 0.05, **p < 0.005, ***p < 0.001.
















amoeboid morphology (Fig. 3A). Although this characteristic is
generally associated with cell activation, we found no differ-
ences in the basal expression of proinflammatory (iNOS) or
anti-inflammatory markers (MNR) (Fig. 3B) nor in cell viability
(Fig. 3C). However, Mdivi-1 reduced significantly the increased
expression of iNOS in response to LPS and IFN-g stimulation
(Fig. 3D). We further analyzed by qPCR the expression of differ-
ent proinflammatory mediators. Treating microglia with LPS plus
IFN-g induced an increase in all the proinflammatory gene
expression assessed (Ccl2, Il1b, iNOS) (Table I) with respect to
control cells, and also the expression of Arg1, an anti-inflammatory
mediator that is known to carry an opposite function to iNOS
regarding cellular metabolism (14). The treatment with Mdivi-1
significantly reduced proinflammatory mediators overexpression
as well as that of Arg1 (Fig. 3E). These results suggest that
Drp1-dependent mitochondrial fission is potentially involved in
microglial activation.
Next, we checked whether the impact of Mdivi-1 on micro-
glial activation could affect microglia metabolic reprogramming.
In addition to the blockage of Drp1 mitochondrial fission,
Mdivi-1 provoked an acute and reversible inhibition of mito-
chondrial complex I in neurons (38). To determine the direct
impact of Mdivi-1 on microglial bioenergetics, we treated
microglia with Mdivi-1 for 1 h and 24 h, and we measured
microglial OCR. We also observed a reduction in mitochondrial
respiration at 1 h; however, the effect was transient and disap-
peared at 24 h (Fig. 4A, 4B). Next, we analyzed the impact of
Mdivi-1 on the metabolic switch of proinflammatory microglia.
Treatment with Mdivi-1 did not increase OCR levels in cells
stimulated with LPS and IFN-g to recover the normal bioener-
getics profile (Fig. 4B). These results indicate that, although
Drp1-mediated mitochondrial fission could modulate or con-
tribute to microglia activation, it does not play an active role in
the metabolic switch produced in inflammatory paradigms.
TABLE I. List of primers for quantitative real-time PCR





Housekeeping gene Forward sequence (50->30) Reverse sequence (50->30)
Hprt2 CAGTACAGCCCCAAAATGGTTA AGTCTGGCCTGTATCCAACA
Ppia AGGGTTCCTCCTTTCACAGAA TGCCGCCAGTGCCATTA
Primers were designed using Primer Express Software (Applied Biosystems) at exon junctions to avoid genomic DNA amplification.
FIGURE 4. Mitochondrial fission inhibition does not reverse mitochondrial metabolic reprogramming.
(A) Metabolic profile of control and microglia treated for 1 h with Mdivi-1 (above). Histogram shows the metabolic parameters related to OCR of
Mdivi-1–treated cells compared with the control ones (n 5 3). (B) Metabolic profile of control microglia as well as microglia treated for 24 h with
Mdivi-1, LPS plus IFN-g, and Mdivi-1 plus LPS plus IFN-g. Histograms show the metabolic parameters related to OCR compared with control micro-
glia (n 5 3). Data are presented as means 6 SEM. One-way ANOVA followed by Bonferroni post hoc analysis was used. *p < 0.05, ***p < 0.001.
















Mdivi-1 treatment does not improve microglial
repolarization
Redirection of microglia from a detrimental to a regenerative
phenotype is a major concept for developing new therapies tar-
geting these cells (39). NO, the product of iNOS activity, blunts
mitochondrial respiration of proinflammatory macrophages, and
this dysfunction prevents editing the macrophage toward an
anti-inflammatory phenotype. Thus, inhibiting NO production
improves mitochondrial metabolic impairment and macrophages
reprogramming toward an anti-inflammatory phenotype (40).
Given that Mdivi-1 reduced iNOS expression in proinflammatory
microglia, we assessed the capacity of Mdivi-1 to promote repo-
larization in microglia. To that end, microglia cells were primed
for 24 h with LPS plus IFN-g (with or without Mdivi-1, to
reduce NO production) and then treated 24 h with anti-inflam-
matory cytokines (see scheme in Fig. 5A). We first compared the
IL-4 plus IL-13induced response in cells previously primed
with LPS plus IFN-g with the response of cells exposed to anti-
inflammatory stimulus only. After exposure to IL-4 plus IL-13,
microglia primed with LPS plus IFN-g exhibited efficient upre-
gulation in the expression of the anti-inflammatory marker
MNR and downregulation in the expression of iNOS (Fig. 5B).
The expression of iNOS and MNR were further reduced or
increased, respectively, in cells treated with Mdivi-1 during LPS
plus IFN-g priming (Fig. 5B). When the metabolic profile of the
cells was assessed using the Seahorse XFe96 Analyzer, we
observed that microglia primed with LPS plus IFN-g partially
recovered the mitochondrial respiration after exposure to IL-4
plus IL-13 (Fig. 5C). However, Mdivi-1 treatment during LPS
plus IFN-g priming did not further enhance the final OCR and
therefore the OXPHOS activity (Fig. 5C). These results do not
support the implication of mitochondrial dynamics in the repo-
larization process of microglia.
DISCUSSION
Immunometabolism has recently emerged as an important
focus of research, as it opens a novel therapeutic approach for
inflammatory and autoimmune diseases. To conduct some
responses, effector immune cells, such as microglia/macro-
phages, undergo a metabolic reprogramming process (5, 7). In
this study, we have monitored this effect in primary microglia
and its consequences in mitochondrial integrity; moreover, we
have checked whether this metabolic switch is associated with
mitochondrial fission. It is noteworthy to mention that the abla-
tion of OXPHOS in active cells is not due to a challenge to
FIGURE 5. Mdivi-1 treatment does not promote microglial repolarization.
(A) Scheme of the conditions used to study the role of Mdivi-1 in the repolarization capacity of microglia. Each treatment indicated lasts 24 h. Anti-
inflammatory microglia (treated with ILs) were compared with microglia that were primed for 24 h with LPS plus IFN-g before 24-h treatment with
ILs. (B) Expression of anti-inflammatory (MRC1) and proinflammatory (iNOS) markers in every condition of the repolarization experiment. Histo-
grams represent the mean 6 SEM of the marker fluorescence intensity per cell (n 5 3 experiments performed in triplicate). (C) Metabolic profile
(left) of microglia treated as schematized in (A). Histograms (right) show metabolic parameters regarding OCR of the cells (n 5 3). Data were
expressed as fold change versus control nontreated microglia. Data are presented as means 6 SEM. *p < 0.05, **p < 0.005, ***p < 0.001 by Stu-
dent t test.
















mitochondrial integrity. Moreover, we have shown that Drp1-
dependent mitochondrial fission, although potentially involved
in microglial activation, does not play an essential role in meta-
bolic reprogramming of microglia.
Upon proinflammatory stimulation, cells are able to redirect
their entire metabolic processes to the glycolytic pathway to
rapidly obtain energy. This process is an outcome of different
molecular pathways; nevertheless, the precise mechanisms
involved are yet to be defined. In this study, we have observed
that, although the OXPHOS machinery is completely halted,
this is not associated with mitochondrial damage or dysfunction
nor with microglia cell death. This is opposed to what was
observed when the Warburg effect was first described; it was
hypothesized that dysfunctional mitochondria would be the
reason underlying the switch in metabolism and, eventually,
the development of cancer cells (41). However, recent studies
have highlighted the importance of mitochondria regarding the
production of ROS as agents to support not only the develop-
ment of cancer cells but also the proinflammatory state of mac-
rophages (42, 43), suggesting no mitochondrial dysfunctionality.
Thus, TLR activation in macrophages induced mitochondrial
ROS generation, an essential step for efficient intracellular bac-
teria killing (43). We observed that DCm was maintained in
proinflammatory microglia through the reverse operation of
F0F1-ATP synthase and that this protects microglia from cell
death. Indeed, the blockage of complex I, III, and IV abolishes
H1 translocation and it would lead to a transient drop in DCm.
However, the F1 subunit of F0F1-ATP synthase can hydrolyze
mitochondrial ATP under these circumstances and drives the
F0 rotor to pump H1 out of the matrix to be able to maintain
the DCm (44). Thus, the mitochondria of proinflammatory
microglia would become consumers rather than ATP genera-
tors, further increasing the energetic demand of these cells
(45). We have not found any essential role in the ANT reversal
activity, which has also been described as key in the DCm
maintenance process in similar paradigms (35).
Signaling events mediated by extracellular signals can regu-
late the metabolic pathways in immune cells such as macro-
phages or microglia (46). Accordingly, diverse cellular functions
have been associated with metabolic reprogramming, including
those related to mitochondrial function in general. Previous
data suggested that mitochondrial dynamics contribute to this
mechanism (9). Our results demonstrated that Mdivi-1, a puta-
tive mitochondrial fission inhibitor, reduced the enhancement
of markers associated with microglial activation after LPS and
IFN-g exposure. This effect on microglial activation is in agree-
ment with other studies, even in other paradigms of treatment
(9, 37). Drp1-mediated mitochondrial fission has been associ-
ated with enhanced activation of both p38 and NF-kb, both
mediators of signaling cascades leading to the expression of
proinflammatory genes, in a paradigm of diabetic nephropathy
(47). Moreover, blocking Drp1-dephosphorylation with oleuro-
pein reduced the production of proinflammatory factors in
microglia as well (48). In contrast, blockage of mitochondrial
fission with Mdivi-1 did not avoid the microglial metabolism
switch to glycolysis upon LPS plus IFN-g exposure, nor did it
provoke any effect in the control cells. We concluded that mito-
chondria fission does not contribute to the metabolic switch in
microglia. This result is apparently at odds with previous
results (9). The contradiction may be explained on the basis of
the different paradigm used; in the Nair and colleagues study
(9), microglia was pretreated with Mdivi-1 (25 mM) for 1 h
before LPS stimulation (100 ng/ml. 24 h). We, in contrast,
blocked mitochondrial fission with Mdivi-1 (50 mM) during the
whole LPS (10 ng/ml) plus IFN-g (20 ng/ml) treatment (24 h).
Distinct arginine metabolism plays a key role in the meta-
bolic plasticity of immune cells. Proinflammatory microglia
convert arginine into NO trough iNOS activity, which is
increased in this phenotype (14, 49). It has been described that
the upregulation of iNOS and the resulting generation of NO
contributes to the impairment of mitochondrial respiration
both in immune cells and astrocytes (50, 51). Moreover, editing
macrophage and microglia (re)polarization is emerging as a
new therapeutic approach, and iNOS has been described as a
target. Actually, iNOS inhibition improves metabolic and phe-
notypic reprograming to anti-inflammatory macrophages (40).
Despite that Mdivi-1 treatment consistently reduced iNOS
expression in proinflammatory microglia, we did not detect any
significant improvement on mitochondrial respiration. There
are two possible interpretations. The complete blockage of
iNOS activity and total abolishment of NO production, as
observed with the iNOS inhibitor 1400W (52), could be
required to prevent the metabolic switch. In this sense, Mdivi-1
only partially reduced iNOS expression in proinflammatory
microglia. Alternatively, signaling pathways controlling meta-
bolic switch could differ from those regulating phenotypic and
inflammatory expression. Indeed, iNOS inhibition does not
affect phenotypic polarization of cells nor the inflammatory
cytokine secretion of macrophages (40). Accordingly, the effect
of Mdivi-1 on proinflammatory gene expression does not pro-
duce any change on metabolism. For instance, Mdivi-1 rapidly
and reversibly attenuated complex I-dependent reverse electron
transfer-mediated ROS production by brain mitochondria oxi-
dizing succinate (20).
In summary, the current study sheds some light into the
role of mitochondria in the metabolic reprogramming process
in microglia. Proinflammatory stimuli dampen mitochondrial
function without compromising their integrity, and our results
point to F0F1-ATP synthase as a key regulator of mitochondrial
potential and cell viability maintenance in these conditions.
However, we concluded that mitochondrial dynamics,
fusionfission, although potentially involved in proinflamma-
tory gene expression, do not contribute to microglial glycolytic
switch after proinflammatory stimulation.
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